Eli Lilly and Co

🇺🇸United States
Ownership
-
Employees
43K
Market Cap
$859.4B
Website
Introduction

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials
Related News

A Study of Visual Effects of Erectile Dysfunction Medications Dosed Daily for Six Months

Phase 4
Completed
Conditions
Erectile Dysfunction
First Posted Date
2006-06-02
Last Posted Date
2007-10-25
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
198
Registration Number
NCT00333281
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States

Study of Hot Flashes and Night Sweats in Postmenopausal Women Receiving Combination Raloxifene and Oral Estrogen

Phase 2
Completed
Conditions
Vasomotor Symptoms
Endometrial Safety
First Posted Date
2006-06-01
Last Posted Date
2007-05-15
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
150
Registration Number
NCT00332553
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877- CTLILLY (1-877-285-4559, 1-317-615-4559) Mon-Fri from 9AM to 5PM Eastern Time (UTC/GMT-5 hours, EST), or speak with your personal physician., Indianapolis, Indiana, United States

PRELUDE:Study to Investigate the Prevention of Relapse in Lymphoma Using Daily Enzastaurin

Phase 3
Completed
Conditions
Non Hodgkin Lymphoma
Interventions
Drug: placebo
Drug: enzastaurin
First Posted Date
2006-06-01
Last Posted Date
2018-09-10
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
758
Registration Number
NCT00332202
Locations
🇬🇧

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., London, United Kingdom

A Study of Pemetrexed and Folic Acid Given Before Surgery (Neoadjuvant Treatment) to Patients With Rectal Cancer.

Phase 2
Completed
Conditions
Rectal Neoplasms
Interventions
Drug: pemetrexed
First Posted Date
2006-05-29
Last Posted Date
2009-07-21
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
37
Registration Number
NCT00330915
Locations
🇸🇪

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Göteborg, Sweden

A Concordance Study Comparing Insulin Treatments in Patients With Type 2 Diabetes

First Posted Date
2006-05-26
Last Posted Date
2019-09-16
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
1019
Registration Number
NCT00330473
Locations
🇿🇦

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Pretoria, South Africa

Effects of LY2062430 in Subjects With Mild-to-Moderate Alzheimer's Disease and in Healthy Volunteers

Phase 2
Completed
Conditions
Alzheimer's Disease
Interventions
Drug: LY2062430
Drug: Placebo
First Posted Date
2006-05-24
Last Posted Date
2009-10-07
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
25
Registration Number
NCT00329082
Locations
🇺🇸

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Philadelphia, Pennsylvania, United States

Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic Cancer

First Posted Date
2006-05-17
Last Posted Date
2011-05-25
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
61
Registration Number
NCT00326911
Locations
🇺🇸

ImClone Investigational Site, Dallas, Texas, United States

Pemetrexed-Carboplatin and Gemcitabine-Vinorelbine in Advanced Breast Cancer

First Posted Date
2006-05-12
Last Posted Date
2011-05-20
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
135
Registration Number
NCT00325234
Locations
🇹🇷

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Kayseri, Turkey

Study of Human Insulin Inhalation Powder in Patients With Type 2 Diabetes

First Posted Date
2006-05-12
Last Posted Date
2019-09-16
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
415
Registration Number
NCT00325364
Locations
🇨🇳

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Yungkang City, Taiwan

Patient's Preference Between Conventional Oral Olanzapine Tablet vs Olanzapine Orodispersible Tablet

Phase 4
Completed
Conditions
Schizophrenia
First Posted Date
2006-05-10
Last Posted Date
2019-09-12
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
284
Registration Number
NCT00324051
Locations
🇹🇷

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Istanbul, Turkey

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy